Next Article in Journal
New Insights into the Crossroads between EMT and Stemness in the Context of Cancer
Next Article in Special Issue
Considering Exosomal miR-21 as a Biomarker for Cancer
Previous Article in Journal
Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population
Previous Article in Special Issue
Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(3), 36; doi:10.3390/jcm5030036

MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
*
Author to whom correspondence should be addressed.
Academic Editors: Takahiro Ochiya and Ryou-u Takahashi
Received: 4 December 2015 / Revised: 23 February 2016 / Accepted: 1 March 2016 / Published: 9 March 2016
(This article belongs to the Special Issue MicroRNAs: Novel Biomarkers and Therapeutic Targets for Human Cancers)
View Full-Text   |   Download PDF [559 KB, uploaded 9 March 2016]   |  

Abstract

Lung cancer is the leading cause of cancer death in men and women worldwide. The lack of specific and sensitive tools for early diagnosis as well as still-inadequate targeted therapies contribute to poor outcomes. MicroRNAs are small non-coding RNAs, which regulate gene expression post-transcriptionally by translational repression or degradation of target mRNAs. A growing body of evidence suggests various roles of microRNAs including development and progression of lung cancer. In lung cancer, several studies have showed that certain microRNA profiles classified lung cancer subtypes, and that specific microRNA expression signatures distinguished between better-prognosis and worse-prognosis lung cancers. Furthermore, microRNAs circulate in body fluids, and therefore may serve as promising biomarkers for early diagnosis of lung cancer as well as for predicting prognosis of patients. In the present review, we briefly summarize microRNAs in the development and progression of lung cancer, focusing on possible applications of microRNAs as novel biomarkers and tools for treatment. View Full-Text
Keywords: adenocarcinoma; carcinoma; driver mutation; histology; miRNA; molecular pathology; morphology; plasma; mutation; oncology; serum; sputum adenocarcinoma; carcinoma; driver mutation; histology; miRNA; molecular pathology; morphology; plasma; mutation; oncology; serum; sputum
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Inamura, K.; Ishikawa, Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J. Clin. Med. 2016, 5, 36.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top